Supernus (SUPN) | Stock Overview & Key Data
Supernus Performance Comparison
Stock Range
Today's Range
Low: $43.49
High: $45.01
on August 22, 2025
52 Week Range
Low: $29.16
High: $45.01
on May 7, 2025
on August 22, 2025
All-Time High: $61.25 on June 25, 2018
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$2.5B
EPS
1.15
P/E Ratio (TTM)
39.03
Forward P/E
23.75
P/B Ratio
2.37
PEG Ratio
3.51
Div. Yield
N/A
ROE
6.38%
Beta
0.742
Debt to Equity
2.99
Financial Highlights
Profitability
Gross Margin
89.83%
Operating Margin
6.73%
Profit Margin
9.70%
Returns and Earnings
Return on Assets (TTM)
2.39%
Return on Equity (TTM)
6.38%
EBITDA
$168.6M
Net Income (TTM)
$64.5M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$11.93
Quarterly Revenue Growth (YoY)
-1.70%
Quarterly Earnings Growth (YoY)
13.00%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Supernus SUPN | 2.52B Mid-cap | 5.13% | 37.37% | 40.07% | 37.33% | 23.20% | 28.34% | 32.62% | 102.80% |
| Zoetis ZTS | 65.30B Large-cap | 1.63% | 3.59% | -3.30% | -5.26% | -3.68% | -13.42% | -2.05% | -2.11% |
| Haleon Plc - ADR HLN | 44.69B Large-cap | 1.76% | 1.76% | -11.21% | -3.25% | 4.03% | -0.81% | 57.62% | 32.52% |
| Elanco Animal Health ELAN | 8.69B Mid-cap | -0.28% | 19.96% | 41.36% | 61.21% | 48.63% | 22.92% | 16.45% | -38.52% |
| Regencell Bioscience RGC | 6.38B Mid-cap | -2.44% | -6.36% | 10.15% | 10,566.67% | 9,746.15% | 5,718.18% | 1,562.34% | 4,471.43% |
| Alkermes plc ALKS | 4.91B Mid-cap | 2.41% | 10.06% | -1.00% | -16.24% | 3.48% | 6.44% | 21.23% | 81.96% |
Ownership & Short Interest
Insider Ownership
4.19%
Institutional Ownership
109.43%
Shares Short
5M
Short Ratio
6.80
Short % of Shares Outstanding
12.91%
Average 10-Day Volume
854K
Average 90-Day Volume
969K
Supernus Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Supernus would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is SUPN's 52-week high and low?
- In the last 52 weeks, Supernus reached a high of $45.01 (on August 22, 2025) and a low of $29.16 (on May 7, 2025).
- What is the market cap and P/E ratio for SUPN?
- Curious about Supernus's size and valuation? Its market capitalization stands at 2.52B. When it comes to valuation, the P/E ratio (trailing twelve months) is 39.03, and the forward P/E (looking ahead) is 23.75.
- Does SUPN pay dividends? If so, what's the yield?
- As for dividends, Supernus isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Supernus's main competitors or similar companies to consider before investing?
When looking at Supernus, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Zoetis
ZTS65.30B Healthcare Drug Manufacturers - Specialty & Generic -13.42% -2.05% Haleon Plc - ADR
HLN44.69B Healthcare Drug Manufacturers - Specialty & Generic -0.81% 57.62% Elanco Animal Health
ELAN8.69B Healthcare Drug Manufacturers - Specialty & Generic 22.92% 16.45% Regencell Bioscience
RGC6.38B Healthcare Drug Manufacturers - Specialty & Generic 5,718.18% 1,562.34% Alkermes plc
ALKS4.91B Healthcare Drug Manufacturers - Specialty & Generic 6.44% 21.23% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Supernus Pharmaceuticals Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Supernus's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 6.38%, the Debt to Equity ratio from the most recent quarter is 2.99, and its Gross Profit Margin stands at 89.83%.
- What is the recent revenue and earnings growth for SUPN?
- Looking at Supernus's growth, its revenue over the trailing twelve months (TTM) was $665M. Compared to the same quarter last year (YoY), quarterly revenue grew by -1.70%, and quarterly earnings saw a YoY growth of 13.00%.
- How much of SUPN stock is held by insiders and institutions?
- Wondering who owns Supernus stock? Company insiders (like executives and directors) hold about 4.19% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 109.43%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.